# US 2026/0294970 A1 · Chimeric cytokine receptors and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0294970 A1
- Document ID: US20260294970A1
- Status: Published application
- Kind: A1
- Application number: 19/480,131
- Filed: 2024-07-31
- Published: 2026-10-01
- Earliest claimed: 2023-07-31
- Assignees: Legend Biotech USA Inc.
- Applicants: Legend Biotech USA Inc.
- Inventors: Qingling Jiang; Yafeng ZHANG; Chunjing Wu
- Web page: https://patentgrep.com/patent/US20260294970A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/18: against material from animals or humans
- C07K 16/40: against enzymes
- C12N 5/0636: {T lymphocytes}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2239/31: characterized by the route of administration
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/03: containing a transmembrane segment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are chimeric cytokine receptors, immune cells expressing the chimeric cytokine receptors and uses thereof.

## Claims

### Claim 1

A chimeric cytokine receptor comprising:
(a) a first extracellular antigen binding domain,
(b) a first transmembrane domain,
(c) a Janus Kinase (JAK)-binding domain comprising a TPOR BOX1 motif, wherein optionally the JAK-binding domain does not comprise a TPOR BOX2 motif, and
(d) a cytokine receptor intracellular domain.

### Claim 2 (depends on 1)

The chimeric cytokine receptor of claim 1, wherein the first transmembrane domain is a TPOR transmembrane domain, a CD28 transmembrane domain, a CD8 transmembrane domain or a DAP10 transmembrane domain.

### Claim 3 (depends on 1, 2)

The chimeric cytokine receptor of claim 1 or 2, wherein the JAK-binding domain comprises an amino acid sequence set forth in SEQ ID NO: 8 or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 8.

### Claim 4

A chimeric cytokine receptor comprising:
(a) a first extracellular antigen binding domain,
(b) a first transmembrane domain, wherein the first transmembrane domain is selected from a CD28 transmembrane domain, a CD8 transmembrane domain and a DAP10 transmembrane domain,
(c) a JAK-binding domain, and
(d) a cytokine receptor intracellular domain.

### Claim 5 (depends on 4)

The chimeric cytokine receptor of claim 4, wherein the JAK-binding domain comprises a TPOR BOX1 motif and a TPOR BOX2 motif.

### Claim 6 (depends on 5)

The chimeric cytokine receptor of claim 5, wherein the JAK-binding domain comprises an amino acid sequence set forth in SEQ ID NO: 7 or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 7.

### Claim 7 (depends on 4)

The chimeric cytokine receptor of claim 4, wherein the JAK-binding domain comprises a TPOR BOX1 motif, and wherein the JAK-binding domain does not comprise a TPOR BOX2 motif.

### Claim 8 (depends on 7)

The chimeric cytokine receptor of claim 7, wherein the JAK-binding domain comprises an amino acid sequence set forth in SEQ ID NO: 8 or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 8.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The chimeric cytokine receptor of any one of claims 1-8, wherein the cytokine receptor intracellular domain comprises a STAT-binding domain, wherein optionally the STAT-binding domain comprises an IL-21R intracellular domain and/or an IL-15Rβ intracellular domain.

### Claim 10 (depends on 9)

The chimeric cytokine receptor of claim 9, wherein the IL-21R intracellular domain comprises an amino acid sequence set forth in SEQ ID NO: 20 or 21 or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 20 or 21.

### Claim 11 (depends on 9)

The chimeric cytokine receptor of claim 9, wherein the IL-15Rβ intracellular domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 10-18 or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 10-18.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The chimeric cytokine receptor of any one of claims 1-11, wherein the first extracellular antigen binding domain binds to an antigen expressed on the surface of a tumor cell.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The chimeric cytokine receptor of any one of claims 1-12, wherein the first extracellular antigen binding domain is derived from NKG2D, truncated NKG2D, a NKG2D extracellular domain, an antibody or antigen binding fragment thereof targeting NKG2D ligands, TIGIT or SIRP-α, or a variant thereof.

### Claim 14 (depends on 12, 13)

The chimeric cytokine receptor of claim 12 or 13, wherein the first extracellular antigen binding domain is derived from NKG2D or truncated NKG2D, or a variant thereof, wherein optionally the first extracellular antigen binding domain is derived from the extracellular domain (ECD) of NKG2D or truncated NKG2D, and wherein optionally the first extracellular antigen binding domain comprises the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 6.

### Claim 15 (depends on 13, 14)

The chimeric cytokine receptor of claim 13 or 14, wherein the chimeric cytokine receptor comprises the amino acid sequence of SEQ ID NO: 103, 105, 107, 109 or 111, or an amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 103, 105, 107, 109 or 111.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A cell comprising the chimeric cytokine receptor of any one of claims 1-15.

### Claim 17 (depends on 16)

The cell of claim 16, wherein the cell further comprises a functional exogenous receptor.

### Claim 18 (depends on 17)

The cell of claim 17, wherein the functional exogenous receptor comprising: (a) a second extracellular antigen binding domain, (b) a second transmembrane domain, and (c) an intracellular signaling domain.

### Claim 19 (depends on 18)

The cell of claim 18, wherein the functional exogenous receptor is a T cell receptor (TCR), a chimeric antigen receptor (CAR), a chimeric TCR (cTCR), or a T cell antigen coupler (TAC)-like chimeric receptor.

### Claim 20 (depends on 19)

The cell of claim 19, wherein the functional exogenous receptor is a CAR, wherein optionally the CAR is a single CAR, dual CAR, tandem CAR or split CAR.

### Claim 21 (depends on 19, 20)

The cell of claim 19 or 20, wherein the CAR binds to a tumor-associated antigen, wherein optionally the tumor-associated antigen is selected from the group consisting of CD19, AFP, BCMA, NY-ESO-1, VEGFR2, MAGE-A3, CD20, CD22, CD30, CD33, GUCY2C, MUC17, FGFR2, CLL1, CD38, CEA, CS1, CD138, CD123/IL3Rα, c-Met, gp100, MUC1, IGF-I receptor, EpCAM, CEA, EGFR (such as EGFRVIII), GD2, HER2, IGF1R, mesothelin, PSMA, ROR1, WT1, Glypican 3 (GPC3), Guanylate cyclase 2C (GCC), DLL3, Claudin18.2, Claudin6, Glycolipid F77, PD-L1, PD-L2, and other tumor antigens with clinical significance, and combinations thereof.

### Claim 22 (depends on 19, 20, 21)

The cell of any one of claims 19-21, wherein the CAR comprises a single chain variable fragment (scFv) comprising:
a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 38, 39, 40, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 41, 42, 43, respectively;
(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 44, 45, 46, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 47, 48, 49, respectively;
(3) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 50, 51, 52, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 53, 54, 55, respectively; and
(4) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 97, 98, 99, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 100, 101, 102, respectively.

### Claim 23 (depends on 22)

The cell of claim 22, wherein the CAR comprises a heavy chain variable region (VH) comprising an amino acid sequence that is at least 80% identical to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence that is at least 80% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:
(1) the selected VH sequence is SEQ ID NO: 72, and the selected VL sequence is SEQ ID NO: 73;
(2) the selected VH sequence is SEQ ID NO: 74, and the selected VL sequence is SEQ ID NO: 75;
(3) the selected VH sequence is SEQ ID NO: 76, and the selected VL sequence is SEQ ID NO: 77; and
(4) the selected VH sequence is SEQ ID NO: 94, and the selected VL sequence is SEQ ID NO: 95.

### Claim 24 (depends on 19, 20, 21)

The cell of any one of claims 19-21, wherein the CAR comprises a VHH antibody moiety that having the amino acid sequences of:
(1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 56, a CDR2 comprising the amino acid sequence of SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 58;
(2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 59, a CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 61;
(3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 62, a CDR2 comprising the amino acid sequence of SEQ ID NO: 63, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 64; or
(4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 65, a CDR2 comprising the amino acid sequence of SEQ ID NO: 66, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 67.

### Claim 25 (depends on 24)

The cell of claim 24, wherein the CAR comprises a VHH antibody moiety comprising the amino acid sequences of any one of SEQ ID NOs: 68-71 or an amino acid sequence having at least 90%, 95%, or 99% identity to the amino acid sequence of any one of SEQ ID NOs: 68-71.

### Claim 26 (depends on 18, 19, 20, 21, 22, 23, 24, 25)

The cell of any one of claims 18-25, wherein the intracellular signaling domain comprises a primary intracellular signaling domain of a cell, wherein optionally the primary intracellular signaling domain is from CD34.

### Claim 27 (depends on 18, 19, 20, 21, 22, 23, 24, 25, 26)

The cell of any one of claims 18-26, wherein the intracellular signaling domain comprises a co-stimulatory signaling domain, wherein optionally the co-stimulatory signaling domain is derived from a co-stimulatory molecule selected from the group consisting of CD27, CD28, CD137, OX40, CD30, CD40, CD3, LFA-1, ICOS, CD2, CD7, LIGHT, NKG2C, B7-H3, ligands of CD83 and combinations thereof.

### Claim 28 (depends on 19, 20, 21, 22, 23, 24, 25, 26, 27)

The cell of any one of claims 19-27, wherein the CAR comprises an amino acid sequence set forth in any one of SEQ ID NOs: 4, 78-83 and 91, or an amino acid sequence having at least 90%, 95%, or 99% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 4, 78-83 and 91.

### Claim 29 (depends on 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The cell of any one of claims 17-28, wherein the chimeric cytokine receptor and the functional exogenous receptor are linked to each other via a peptide linker.

### Claim 30 (depends on 29)

The cell of claim 29, wherein the peptide linker is a self-cleaving peptide linker, wherein optionally the self-cleaving peptide linker is a 2A self-cleaving peptide, wherein optionally the 2A self-cleaving peptide is selected from a group consisting of F2A, E2A, P2A, T2A, and variants thereof.

### Claim 31 (depends on 29, 30)

The cell of claim 29 or 30, wherein the cell comprises the amino acid sequence set forth in any one of SEQ ID NOs: 22-37, 92 and 93, or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 22-37, 92 and 93.

### Claim 32 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The cell of any one of claims 16-31, wherein the cell is an immune cell.

### Claim 33 (depends on 32)

The cell of claim 32, wherein the immune cell is selected from a group consisting of T cell, NK cell, NKT, peripheral blood mononuclear cell (PBMC), hematopoietic stem cell, pluripotent stem cell, an embryonic stem cell, a macrophage, a monocyte, a neutrophil, an eosinophil and a combination thereof.

### Claim 34 (depends on 33)

The cell of claim 33, wherein the T cell is a αβT cell, γδT cell or a combination of αβT and γδT cell.

### Claim 35 (depends on 33)

The cell of claim 33, wherein the T cell, upon activation, exhibits increased expression of pSTAT3 and pSTAT5.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A nucleic acid comprising a nucleic acid sequence encoding the chimeric cytokine receptor of any one of claims 1-15.

### Claim 37 (depends on 36)

The nucleic acid of claim 36, wherein the nucleic acid further comprises a nucleic acid sequence encoding a functional exogenous receptor comprising: (a) a second extracellular antigen binding domain, (b) a second transmembrane domain, and (c) an intracellular signaling domain.

### Claim 38 (depends on 37)

The nucleic acid of claim 37, wherein the functional exogenous receptor is a T cell receptor (TCR), a chimeric antigen receptor (CAR), a chimeric TCR (cTCR), or a T cell antigen coupler (TAC)-like chimeric receptor.

### Claim 39 (depends on 38)

The nucleic acid of claim 38, wherein the CAR binds to a tumor-associated antigen, wherein optionally the tumor-associated antigen is selected from the group consisting of CD19, AFP, BCMA, NY-ESO-1, VEGFR2, MAGE-A3, CD20, CD22, CD30, CD33, GUCY2C, MUC17, FGFR2, CLL1, CD38, CEA, CS1, CD138, CD123/IL3Rα, c-Met, gp100, MUC1, IGF-I receptor, EpCAM, CEA, EGFR (such as EGFRvIII), GD2, HER2, IGF1R, mesothelin, PSMA, ROR1, WT1, Glypican 3 (GPC3), Guanylate cyclase 2C (GCC), DLL3, Claudin18.2, Claudin6, Glycolipid F77, PD-L1, PD-L2, and other tumor antigens with clinical significance, and combinations thereof.

### Claim 40 (depends on 38, 39)

The nucleic acid of claim 38 or 39, wherein the CAR comprises a single chain variable fragment (scFv) comprising:
a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence; and
a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
(1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 38, 39, 40, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 41, 42, 43, respectively;
(2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 44, 45, 46, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 47, 48, 49, respectively;
(3) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 50, 51, 52, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 53, 54, 55, respectively; and
(4) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 97, 98, 99, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs: 100, 101, 102, respectively.

### Claim 41 (depends on 40)

The nucleic acid of claim 40, wherein the CAR comprises a heavy chain variable region (VH) comprising an amino acid sequence that is at least 80% identical to a selected VH sequence, and a light chain variable region (VL) comprising an amino acid sequence that is at least 80% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:
(1) the selected VH sequence is SEQ ID NO: 72, and the selected VL sequence is SEQ ID NO: 73;
(2) the selected VH sequence is SEQ ID NO: 74, and the selected VL sequence is SEQ ID NO: 75;
(3) the selected VH sequence is SEQ ID NO: 76, and the selected VL sequence is SEQ ID NO: 77; and
(4) the selected VH sequence is SEQ ID NO: 94, and the selected VL sequence is SEQ ID NO: 95.

### Claim 42 (depends on 38, 39)

The nucleic acid of claim 38 or 39, wherein the CAR comprises a VHH antibody moiety that having the amino acid sequences of:
(1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 56, a CDR2 comprising the amino acid sequence of SEQ ID NO: 57, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 58;
(2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 59, a CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 61;
(3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 62, a CDR2 comprising the amino acid sequence of SEQ ID NO: 63, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 64; or
(4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 65, a CDR2 comprising the amino acid sequence of SEQ ID NO: 66, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 67.

### Claim 43 (depends on 42)

The nucleic acid of claim 42, wherein the CAR comprises a VHH antibody moiety comprising an amino acid sequence of any one of SEQ ID NOs: 68-71 or an amino acid sequence having at least 90%, 95%, or 99% identity to the amino acid sequence of any one of SEQ ID NOs: 68-71.

### Claim 44 (depends on 37, 38, 39, 40, 41, 42, 43)

The nucleic acid of any one of claims 37-43, wherein the intracellular signaling domain further comprises a co-stimulatory signaling domain.

### Claim 45 (depends on 38, 39, 40, 41, 42, 43, 44)

The nucleic acid of any one of claims 38-44, wherein the CAR comprises an amino acid sequence set forth in any one of SEQ ID NOs: 4, 78-83 and 91, or an amino acid sequence having at least 90%, 95%, or 99% identity to the amino acid sequence set forth in any one of SEQ ID NOs: 4, 78-83 and 91.

### Claim 46 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45)

The nucleic acid of any one of claims 37-45, wherein the chimeric cytokine receptor nucleic acid sequence and the nucleic acid sequence encoding the functional exogenous receptor are linked to each other via a third nucleic acid sequence encoding a peptide linker.

### Claim 47 (depends on 46)

The nucleic acid of claim 46, wherein the nucleic acid comprises a nucleic acid sequence encoding an amino acid sequence set forth in any one of SEQ ID NOs: 22-37, 92 and 93, or an amino acid sequence that is at least 80%, 85%, 90%, 95% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 22-37, 92 and 93.

### Claim 48 (depends on 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A vector comprising the nucleic acid of any one of claims 36-47.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A pharmaceutical composition, comprising the chimeric cytokine receptor of any one of claims 1-15, the cell of any one of claims 16-35, or the nucleic acid of any one of claims 36-47 and a pharmaceutically acceptable carrier.

### Claim 50 (depends on 49)

A method of treating a disease or disorder in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

### Claim 51 (depends on 50)

The method of claim 50, wherein the disease or disorder is a cancer, an inflammatory or autoimmune disease.

### Claim 52 (depends on 51)

The method of claim 51, wherein the cancer is solid cancer or hematologic cancer.

### Claim 53 (depends on 52)

The method of claim 52, wherein the cancer is liver cancer, gastric cancer, colon cancer, lymphoma, acute myeloid leukemia (AML) or chronic myelogenous leukemia (CML).
